Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study
Standard
Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study. / GREAT (Global REsearch on Acute Conditions Team) Network.
In: CLIN RES CARDIOL, Vol. 108, No. 8, 08.2019, p. 940-949.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study
AU - Kanagala, Prathap
AU - Squire, Iain B
AU - Jones, Donald J L
AU - Cao, Thong Huy
AU - Chan, Daniel C S
AU - McCann, Gerry
AU - Sandhu, Jatinderpal K
AU - Quinn, Paulene A
AU - McAdam, John
AU - Marsh, Anna-Marie
AU - Davies, Joan E
AU - Struck, Joachim
AU - Bergmann, Andreas
AU - Sabti, Zaid
AU - Twerenbold, Raphael
AU - Herrmann, Thomas
AU - Kozhuharov, Nikola
AU - Mueller, Christian
AU - Ng, Leong L
AU - GREAT (Global REsearch on Acute Conditions Team) Network
PY - 2019/8
Y1 - 2019/8
N2 - BACKGROUND: Proenkephalin (PENK), a stable endogenous opioid biomarker related to renal function, has prognostic utility in acute and chronic heart failure. We investigated the prognostic utility of PENK in heart failure with preserved ejection fraction (HFpEF), and its relationship to renal function, Body Mass Index (BMI), and imaging measures of diastolic dysfunction.METHODS: In this multicentre study, PENK was measured in 522 HFpEF patients (ejection fraction > 50%, 253 male, mean age 76.13 ± 10.73 years) and compared to 47 age and sex-matched controls. The primary endpoint was 2-years composite of all-cause mortality and/or heart failure rehospitalisation (HF). A subset (n = 163) received detailed imaging studies.RESULTS: PENK levels were raised in HFpEF (median [interquartile range] 88.9 [62.1-132.0]) compared to normal controls (56.3 [47.9-70.5]). PENK was correlated to urea, eGFR, Body Mass Index and E/e' (rs 0.635, - 0.741, - 0.275, 0.476, respectively, p < 0.0005). During 2 years follow-up 144 patients died and 220 had death/HF endpoints. Multivariable Cox regression models showed PENK independently predicted 2 year death/HF [hazard ratio (for 1 SD increment of log-transformed biomarker) HR 1.45 [95% CI 1.12-1.88, p = 0.005]], even after adjustment for troponin (HR 1.59 [1.14-2.20, p = 0.006]), and Body Mass Index (HR 1.63 [1.13-2.33, p = 0.009]). PENK showed no interaction with ejection fraction status for prediction of poor outcomes. Net reclassification analyses showed PENK significantly improved classification of death/HF outcomes for multivariable models containing natriuretic peptide, troponin and Body Mass Index (p < 0.05 for all).CONCLUSIONS: In HFpEF, PENK levels are related to BMI, and measures of diastolic dysfunction and are prognostic for all-cause mortality and heart failure rehospitalisation.
AB - BACKGROUND: Proenkephalin (PENK), a stable endogenous opioid biomarker related to renal function, has prognostic utility in acute and chronic heart failure. We investigated the prognostic utility of PENK in heart failure with preserved ejection fraction (HFpEF), and its relationship to renal function, Body Mass Index (BMI), and imaging measures of diastolic dysfunction.METHODS: In this multicentre study, PENK was measured in 522 HFpEF patients (ejection fraction > 50%, 253 male, mean age 76.13 ± 10.73 years) and compared to 47 age and sex-matched controls. The primary endpoint was 2-years composite of all-cause mortality and/or heart failure rehospitalisation (HF). A subset (n = 163) received detailed imaging studies.RESULTS: PENK levels were raised in HFpEF (median [interquartile range] 88.9 [62.1-132.0]) compared to normal controls (56.3 [47.9-70.5]). PENK was correlated to urea, eGFR, Body Mass Index and E/e' (rs 0.635, - 0.741, - 0.275, 0.476, respectively, p < 0.0005). During 2 years follow-up 144 patients died and 220 had death/HF endpoints. Multivariable Cox regression models showed PENK independently predicted 2 year death/HF [hazard ratio (for 1 SD increment of log-transformed biomarker) HR 1.45 [95% CI 1.12-1.88, p = 0.005]], even after adjustment for troponin (HR 1.59 [1.14-2.20, p = 0.006]), and Body Mass Index (HR 1.63 [1.13-2.33, p = 0.009]). PENK showed no interaction with ejection fraction status for prediction of poor outcomes. Net reclassification analyses showed PENK significantly improved classification of death/HF outcomes for multivariable models containing natriuretic peptide, troponin and Body Mass Index (p < 0.05 for all).CONCLUSIONS: In HFpEF, PENK levels are related to BMI, and measures of diastolic dysfunction and are prognostic for all-cause mortality and heart failure rehospitalisation.
KW - Aged
KW - Biomarkers/blood
KW - Cause of Death/trends
KW - Echocardiography, Doppler
KW - Enkephalins/blood
KW - Female
KW - Glomerular Filtration Rate/physiology
KW - Heart Failure/blood
KW - Heart Ventricles/diagnostic imaging
KW - Humans
KW - Magnetic Resonance Imaging, Cine
KW - Male
KW - Prognosis
KW - Protein Precursors/blood
KW - Stroke Volume/physiology
KW - Survival Rate/trends
KW - Switzerland/epidemiology
U2 - 10.1007/s00392-019-01424-y
DO - 10.1007/s00392-019-01424-y
M3 - SCORING: Journal article
C2 - 30767059
VL - 108
SP - 940
EP - 949
JO - CLIN RES CARDIOL
JF - CLIN RES CARDIOL
SN - 1861-0684
IS - 8
ER -